Boston Scientific Corporation (BSX) is a leading innovator in the global medical device industry. Founded in 1979, the company is headquartered in Marlborough, Massachusetts, and is committed to the transformation of lives through innovative medical solutions that improve the health of patients worldwide. Boston Scientific has established itself as a pioneer in less invasive medicine, a field that has significantly transformed the way several medical conditions are treated.
Boston Scientific Corp operates across various fields, including rhythm and neuro, cardiovascular, and medical surgery. With more than 36,000 employees worldwide, the company reaches over 130 countries, continuously making significant contributions that advance health and well-being. As a testament to its dedication to innovation and healthcare, BSX invests heavily in research and development ($1B+ annually) and have been pioneers in several breakthrough technologies in health and medical sciences.
A particularly striking feature about Boston Scientific Corp is its dedication to improving patient care and well-being. The company's vast product portfolio covers key areas such as cardiac rhythm management, electrophysiology, heart failure, coronary and structural heart, peripheral interventions, urology and pelvic health, gastrointestinal and hepatology, and endoscopy.
The firm's comprehensive approach to healthcare has led to significant improvements in the patient experience, including shorter hospital stays, reduced recovery times, and an enhanced quality of life. The company can achieve this level of success through innovation and the development of advanced technology, combined with clinical expertise and a deep understanding of healthcare providers' needs.
Boston Scientific Corp's long-standing commitment to enhancing lives extends beyond its products. The company is also committed to corporate responsibility, which includes operating ethically, protecting and supporting employees, contributing to healthier communities, and reducing its environmental impact.
A Fortune 500 company, Boston Scientific Corp, with its cutting-edge technological advancements and forward-thinking approaches, remains a significant player in the global medical devices industry. Ultimately, Boston Scientific Corporation embodies its motto - Advancing science for life - by continuously pushing boundaries to improve patients' lives worldwide.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Boston Scientific Corp. (BSX) is trading at a significant discount compared to its historical valuation, driven by weakening earnings expectations and loss of momentum in several key product areas. While the low price-to-earnings ratio might appear attractive, management anticipates performance improvement only by 2028, with 2027 being the trough of the current cycle. The company faces execution risks and intensifying competition, leading to a "Strong Sell" Zacks Rank despite some valuable growth assets and a promising pipeline that is back-end loaded.
Boston Scientific (BSX) reported mixed Q3 2026 results with net sales increasing to $5.138 billion, up from $5.065 billion in Q3 2025, but net income falling to $580 million from $755 million in the prior year. The company's Q3 performance was impacted by a cybersecurity incident disrupting manufacturing and order fulfillment, as well as increased litigation-related charges. Despite these challenges, year-to-date net sales saw a significant increase to $15.784 billion, and the company completed acquisitions of Nalu Medical and Scivita Medical while progressing on the Penumbra acquisition.
McKesson (NYSE: MCK), a healthcare distributor and services company, is set to report its Q3 earnings this Wednesday after market close. The market expects a 6.7% year-on-year revenue growth, a slowdown from the 10.1% increase in the same quarter last year, despite the company beating revenue expectations last quarter. Investors will be watching closely as analyst estimates have remained largely consistent, suggesting a steady performance is anticipated.
Citizens Bank is continuing its strategy of replacing in-store branches at Stop & Shop locations with standalone branches. Meanwhile, JPMorgan Chase is expanding its retail presence in Massachusetts by opening a new location in Quincy. This move reflects ongoing shifts in the physical footprint of banking services in the region.
Boston Scientific Corp. (BSX) stock rallied 5.57% to $44.32 on Monday, outperforming the mixed stock market as the Dow Jones Industrial Average rose and the S&P 500 Index fell. The company's shares closed 58.05% below their 52-week high.
A Texas man has filed a product liability lawsuit against Abbott Laboratories, alleging that their sales representatives prevented him from receiving proper medical treatment after his Proclaim Spinal Cord Stimulator System failed. The lawsuit claims that unlicensed sales reps repeatedly tried to reprogram the malfunctioning device, despite the plaintiff experiencing ineffective pain relief and painful shocking, ultimately leading to the implant's removal less than a year after implantation. This case joins a multidistrict litigation with other similar lawsuits against Abbott, Boston Scientific, and Nevro, focusing on defective spinal cord stimulators and inadequate warnings.
Catheter Precision, a subsidiary of Flyte Aviation, Inc., announced that its VIVO system received FDA 510(k) clearance for expanded use in patients with structural heart disease undergoing catheter ablation for monomorphic ventricular tachycardia. This clearance allows the VIVO system to be used in a broader patient population, improving pre-procedural planning and potentially reducing procedure times and optimizing patient outcomes. The VIVO system is a non-invasive 3D imaging system designed to identify the origin of ventricular arrhythmias prior to an electrophysiology procedure.